时钟基因Period家族在头颈鳞状细胞癌中的研究进展  

Research progress of clock gene Period family in head and neck squamous cell carcinoma

作　　者：叶永英 邹艳 陈天明 吴伟莉 Ye Yongying;Zou Yan;Chen Tianming;Wu Weili(Department of Oncology,School of Clinical Medicine,Guizhou Medical University,Guiyang 550000,China;Department of Oncology,Affiliated Tumor Hospital of Guizhou Medical University,Guiyang 550000,China;Department of Oncology,Affiliated Hospital of Guizhou Medical University,Guiyang 550000,China)

机构地区：[1]贵州医科大学临床医学院肿瘤学教研室,贵阳550000 [2]贵州医科大学附属肿瘤医院肿瘤科,贵阳550000 [3]贵州医科大学附属医院肿瘤科,贵阳550000

出　　处：《国际肿瘤学杂志》2025年第2期113-118,共6页Journal of International Oncology

基　　金：国家自然科学基金(82060555);贵州省科技计划(黔科合基础-ZK[2024]一般208)。

摘　　要：头颈鳞状细胞癌(HNSCC)是最常见的一类异质性恶性肿瘤。超过60%的HNSCC患者在确诊时已处于局部晚期,尽管先进的诊疗措施不断出现,但复发性或转移性HNSCC患者预后仍不理想。Period(PER)基因家族是生物钟基因的重要成员,其家族成员PER1、PER2、PER3在HNSCC中差异表达,参与肿瘤细胞的增殖、凋亡、侵袭或转移等生物学过程,多数研究中表现为抑癌作用,与肿瘤微环境及免疫治疗、时辰化疗等密切相关,是有潜在价值的生物标志物。综合分析PER基因家族在HNSCC中的表达及其在肿瘤的发生发展中发挥的生物学作用与相应分子生物学机制,有助于挖掘其在HNSCC诊断及治疗中的潜在应用价值。Head and neck squamous cell carcinoma(HNSCC)is the most common type of heterogeneous malignant tumor.Over 60%of HNSCC patients are at locally advanced stage at the time of diagnosis.Despite the emergence of advanced diagnosis and treatment measures,the prognosis of patients with recurrent or metastatic HNSCC remains poor.The Period(PER)gene family is an important member of the circadian clock genes,with family members PER1,PER2,and PER3 showing differential expression in HNSCC,participating in biological processes such as proliferation,apoptosis,invasion,or metastasis of tumor cells.In most studies,they exhibit anti-cancer effects and are closely related to the tumor microenvironment,immunotherapy,chronotherapy,etc.,making them potential biomarkers.A comprehensive analysis of the expression of PER gene family in HNSCC,its biological role in the occurrence and development of tumor and the corresponding molecular biological mechanism is helpful to explore its potential application value in the diagnosis and treatment of HNSCC.

关 键 词：头颈鳞癌 预后 分子靶向治疗 肿瘤微环境 Period基因 

分 类 号：R739.91[医药卫生—肿瘤]